Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Next revision		Previous revision
mig [2023/07/03 09:34] – created - external edit 127.0.0.1mig [2024/04/06 15:48] (current) – [Migraine] sflitman
Line 3: Line 3:
 Migraine is arguably the most common neurological condition, affecting up to 80% of adults at some time in their lives. Migraine is arguably the most common neurological condition, affecting up to 80% of adults at some time in their lives.
  
-^ Condition(s)  ^ Type of Drug  ^  Phase  ^  Add-On  ^  Placebo  ^  Duration  ^  Open-Label Extension  ^  +We have no current trials enrolling for migraine, but new opportunities may be posted soon. 
-| Adult episodic migraine preventive |  Novel oral gepant  |  III  |  Yes  |  50%  |   24 weeks  | +
-| Adult episodic migraine preventive + abortive  |  Atogepant + Ubrogepant  |  IV  |  No |  0%  |   52 weeks  |+
 <html><!-- <html><!--
 +
 +^ Condition(s)  ^ Type of Drug  ^  Phase  ^  Add-On  ^  Placebo  ^  Duration  ^  Open-Label Extension  ^
 +| Adult episodic migraine preventive |  Oral Zavegepant  |  III  |  Yes  |  50%  |   24 weeks  |
 +
 +
  
 --></html> --></html>
Line 19: Line 23:
 <div align=right> <div align=right>
  <table border=0 cellspacing=0>  <table border=0 cellspacing=0>
-  <tr><td>Joshua A. Tobin, MD, Director of Migraine Research</td></tr>  +    <tr><td>Stephen S. Flitman, MD, Medical Director</td></tr>
-  <tr><td>Stephen S. Flitman, MD, Medical Director</td></tr>+
  </table>   </table> 
 </div> </div>

Trace:

Print/export
QR Code
QR Code mig (generated for current page)